Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate

Bone

Volumn 49, Issue 6, 2011, Pages 1160-1165

  Gamsjaeger, Sonja ^a   Buchinger, Birgit ^a   Zoehrer, Ruth ^a   Phipps, Roger ^b,c   Klaushofer, Klaus ^a   Paschalis, Eleftherios P ^a  

^a HANUSCH HOSPITAL   (Austria)

^b PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^c HUSSON UNIVERSITY   (United States)

Author keywords

Alendronate; Bone material properties; Collagen cross links; Fourier transform infrared imaging; Mineral maturity; Raman Microspectroscopy; Risedronate; Teriparatide

Indexed keywords

ALENDRONIC ACID; COLLAGEN; PARATHYROID HORMONE[1-34]; PROTEOGLYCAN; RISEDRONIC ACID;

AGED; ARTICLE; BONE MATURATION; BONE MINERALIZATION; CROSS LINKING; DRUG EFFICACY; FEMALE; HUMAN; ILIAC CREST; POSTMENOPAUSE OSTEOPOROSIS; RAMAN SPECTROMETRY; TRABECULAR BONE; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ALENDRONATE; ANALYSIS OF VARIANCE; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE MATRIX; CRYSTALLIZATION; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SPECTRUM ANALYSIS, RAMAN; TERIPARATIDE; TREATMENT OUTCOME;

EID: 81355148868     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.08.015     Document Type: Article

References (46)

1. Hoff A.O., Toth B.B., Altundag K., Johnson M.M., Warneke C.L., Hu M., et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008, 23:826-836.
2. Khosla S., Burr D., Cauley J., Dempster D.W., Ebeling P.R., Felsenberg D., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22:1479-1491.
3. Shane E., Goldring S., Christakos S., Drezner M., Eisman J., Silverman S., et al. Osteonecrosis of the jaw: more research needed. J Bone Miner Res 2006, 21:1503-1505.
4. Shane E., Burr D., Ebeling P.R., Abrahamsen B., Adler R.A., Brown T.D., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25:2267-2294.
5. Compston J. Recombinant parathyroid hormone in the management of osteoporosis. Calcif Tissue Int 2005, 77:65-71.
6. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
7. Pleiner-Duxneuner J., Zwettler E., Paschalis E., Roschger P., Nell-Duxneuner V., Klaushofer K. Treatment of osteoporosis with parathyroid hormone and teriparatide. Calcif Tissue Int 2009, 84:159-170.
8. Canalis E., Giustina A., Bilezikian J.P. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007, 357:905-916.
9. Deal C. Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol 2009, 5:20-27.
10. Kakar S., Einhorn T.A., Vora S., Miara L.J., Hon G., Wigner N.A., et al. Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. J Bone Miner Res 2007, 22:1903-1912.
11. Rawadi G., Roman-Roman S. Wnt signalling pathway: a new target for the treatment of osteoporosis. Expert Opin Ther Targets 2005, 9:1063-1077.
12. Ettinger B., San Martin J., Crans G., Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004, 19:745-751.
13. Boonen S., Marin F., Obermayer-Pietsch B., Simoes M.E., Barker C., Glass E.V., et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2008, 93:852-860.
14. Miller P.D., Delmas P.D., Lindsay R., Watts N.B., Luckey M., Adachi J., et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 2008, 93:3785-3793.
15. Chevalier Y., Quek E., Borah B., Gross G., Stewart J., Lang T., et al. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body. Bone 2010, 46:41-48.
16. Misof B.M., Paschalis E.P., Blouin S., Fratzl-Zelman N., Klaushofer K., Roschger P. Effects of one year daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate. J Bone Miner Res 2010, 25:2297-2303.
17. Rosen C.J., Hochberg M.C., Bonnick S.L., McClung M., Miller P., Broy S., et al. Treatment with once-weekly alendronate 70mg compared with once-weekly risedronate 35mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005, 20:141-151.
18. Gamsjaeger S., Buchinger B., Zwettler E., Recker R., Black D., Gasser J.A., et al. Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly zoledronic acid. J Bone Miner Res 2010, 26:12-18.
19. Gamsjäger S., Kazanci M., Paschalis E., Fratzl P. Raman application in bone imaging. Raman spectroscopy for soft matter applications 2009, 227-269. John Wiley & Sons, Inc., Hoboken, NJ, USA. M. Amer (Ed.).
20. Morris M.D., Mandair G.S. Raman assessment of bone quality. Clin Orthop Relat Res 2011, 469:2160-2169.
21. Paschalis E.P. Fourier transform infrared analysis and bone. Osteoporos Int 2009, 20:1043-1047.
22. Paschalis E.P., Verdelis K., Doty S.B., Boskey A.L., Mendelsohn R., Yamauchi M. Spectroscopic characterization of collagen cross-links in bone. J Bone Miner Res 2001, 16:1821-1828.
23. Lieber C.A., Mahadevan-Jansen A. Automated method for subtraction of fluorescence from biological Raman spectra. Appl Spectrosc 2003, 57:1363-1367.
24. Gentleman E., Swain R.J., Evans N.D., Boonrungsiman S., Jell G., Ball M.D., et al. Comparative materials differences revealed in engineered bone as a function of cell-specific differentiation. Nat Mater 2009, 8:763-770.
25. Gamsjaeger S., Masic A., Roschger P., Kazanci M., Dunlop J.W., Klaushofer K., et al. Cortical bone composition and orientation as a function of animal and tissue age in mice by Raman spectroscopy. Bone 2010, 47:392-399.
26. Kazanci M., Fratzl P., Klaushofer K., Paschalis E.P. Complementary information on in vitro conversion of amorphous (precursor) calcium phosphate to hydroxyapatite from Raman microspectroscopy and wide-angle X-ray scattering. Calcif Tissue Int 2006, 79:354-359.
27. Kazanci M., Roschger P., Paschalis E.P., Klaushofer K., Fratzl P. Bone osteonal tissues by Raman spectral mapping: orientation-composition. J Struct Biol 2006, 156:489-496.
28. Kazanci M., Wagner H.D., Manjubala N.I., Gupta H.S., Paschalis E., Roschger P., et al. Raman imaging of two orthogonal planes within cortical bone. Bone 2007, 41:456-461.
29. Marcott C., Reeder R.C., Paschalis E.P., Tatakis D.N., Boskey A.L., Mendelsohn R. Infrared microspectroscopic imaging of biomineralized tissues using a mercury-cadmium-telluride focal-plane array detector. Cell Mol Biol (Noisy-le-Grand) 1998, 44:109-115.
30. Fratzl P., Gupta H., Paschalis E., Roschger P. Structure and mechanical quality of the collagen-mineral nano-composite in bone. J Mater Chem 2004, 14:2115-2123.
31. Boskey A.L., Pleshko N., Doty S.B., Mendelsohn R. Applications of Fourier Transform Infrared (FT-IR) microscopy to the study of mineralization in bone and cartilage. Cells Mater 1992, 2:209-220.
32. Donnelly E., Chen D.X., Boskey A.L., Baker S.P., van der Meulen M.C. Contribution of mineral to bone structural behavior and tissue mechanical properties. Calcif Tissue Int 2010, 87:450-460.
33. Paschalis E.P., Glass E.V., Donley D.W., Eriksen E.F. Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial. J Clin Endocrinol Metab 2005, 90:4644-4649.
34. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006, 38:617-627.
35. Boskey A.L., DiCarlo E., Paschalis E., West P., Mendelsohn R. Comparison of mineral quality and quantity in iliac crest biopsies from high- and low-turnover osteoporosis: an FT-IR microspectroscopic investigation. Osteoporos Int 2005, 16:2031-2038.
36. Fratzl P., Roschger P., Eschberger J., Abendroth B., Klaushofer K. Abnormal bone mineralization after fluoride treatment in osteoporosis: a small-angle X-ray-scattering study. J Bone Miner Res 1994, 9:1541-1549.
37. Fratzl P., Schreiber S., Roschger P., Lafage M.H., Rodan G., Klaushofer K. Effects of sodium fluoride and alendronate on the bone mineral in minipigs: a small-angle X-ray scattering and backscattered electron imaging study. J Bone Miner Res 1996, 11:248-253.
38. Paschalis E.P., Betts F., DiCarlo E., Mendelsohn R., Boskey A.L. FTIR microspectroscopic analysis of human iliac crest biopsies from untreated osteoporotic bone. Calcif Tissue Int 1997, 61:487-492.
39. Paschalis E.P., Betts F., DiCarlo E., Mendelsohn R., Boskey A.L. FTIR microspectroscopic analysis of normal human cortical and trabecular bone. Calcif Tissue Int 1997, 61:480-486.
40. Paschalis E.P., DiCarlo E., Betts F., Sherman P., Mendelsohn R., Boskey A.L. FTIR microspectroscopic analysis of human osteonal bone. Calcif Tissue Int 1996, 59:480-487.
41. Boskey A.L., Spevak L., Doty S.B., Rosenberg L. Effects of bone CS-proteoglycans, DS-decorin, and DS-biglycan on hydroxyapatite formation in a gelatin gel. Calcif Tissue Int 1997, 61:298-305.
42. Mochida Y., Duarte W.R., Tanzawa H., Paschalis E.P., Yamauchi M. Decorin modulates matrix mineralization in vitro. Biochem Biophys Res Commun 2003, 305:6-9.
43. Paschalis E.P., Shane E., Lyritis G., Skarantavos G., Mendelsohn R., Boskey A.L. Bone fragility and collagen cross-links. J Bone Miner Res 2004, 19:2000-2004.
44. Boskey A.L., Spevak L., Weinstein R.S. Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. Osteoporos Int 2009, 20:793-800.
45. Durchschlag E., Paschalis E.P., Zoehrer R., Roschger P., Fratzl P., Recker R., et al. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. J Bone Miner Res 2006, 21:1581-1590.
46. Henneman Z.J., Nancollas G.H., Ebetino F.H., Russell R.G., Phipps R.J. Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro. J Biomed Mater Res A 2008, 85:993-1000.